Evaxion Biotech AS (EVAX)

US · Healthcare · Biotechnology

$3.22+6.27%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Net profit

$-3.7M

EPS

$-0.50

EPS estimate

$-0.01

EPS came in at -0.50 against a street estimate of -0.01 — a miss of 4900.0%.

Market cap

$28.0M

Forward P/E

3.6

P/B

3.10

Book value

$1.14

EPS (TTM)

$-0.48

52-week high

$12.15

52-week low

$2.77

50-day MA

$3.10

200-day MA

$3.91

Beta

0.27

Analysts rate Evaxion Biotech AS a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $11.25.

Insiders

17.47%

Institutions

10.05%

Fund	Stake
Merck & Co Inc	14.56%
Ikarian Capital, LLC	0.90%
Rathbone Brothers PLC	0.55%
Renaissance Technologies Corp	0.47%
Annis Gardner Whiting Capital Advisors LLC	0.36%
XTX Topco Ltd	0.26%
Rhumbline Advisers	0.26%
Stonepine Capital Management Llc	0.24%

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Evaxion Biotech AS — free to start.

Data updated 2026-09-18.